Want to see JP:4597 full AI Analyst Report?
4597 Stock Chart & Stats
¥27.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥27.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥21.00 - ¥48.00
Previous CloseN/A
Volume8.51M
Average Volume (3M)41.98M
Market Cap
¥7.10B
Enterprise Value¥5.07B
Total Cash (Recent Filing)¥1.57B
Total Debt (Recent Filing)¥86.00M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.53
Shares Outstanding273,414,370
10 Day Avg. Volume52,616,870
30 Day Avg. Volume41,982,023
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.93
Price to Sales (P/S)16.06
P/FCF Ratio-8.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2
Revenue Forecast (FY)¥1.92B
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageA very low debt-to-equity (~0.05) gives the company durable financial flexibility: it reduces refinancing risk, preserves capacity to fund trials or commercialization via equity/partnerships, and supports strategic options over the next several months without immediate solvency pressure.
Healthy Gross MarginA ~41% gross margin in a specialty pharma business indicates structural product-level pricing power and favorable cost of goods. This margin provides a buffer as the company scales commercial efforts and can translate into durable profitability gains if operating leverage is achieved.
Partnering-driven Business ModelA model that combines direct commercialization with collaboration income diversifies revenue sources and de-risks development. Milestones and royalties can provide non-dilutive financing and staggered cash inflections, enabling capital-efficient growth and strategic licensing over the medium term.
Bears Say
Persistent Negative Cash FlowSustained operating and free cash outflows (~-1.12B TTM) mean the company must rely on external funding or partner payments to operate. This persistent cash burn erodes runway, increases dilution or financing risk, and constrains the company's ability to self-fund commercialization in the coming months.
Deep Negative Profitability And Declining RevenueA steeply negative net margin (~-217%) combined with year-over-year revenue decline (~-4.4% TTM) shows the cost base far exceeds sales. Without clear operating leverage or revenue acceleration, profitability is unlikely to normalize, creating structural pressure on cash and returns.
Erosion Of Equity And Negative ROEROE near -55% and declining assets/equity reflect ongoing losses and potential write-downs that reduce shareholder capital. Over months this weakens balance sheet resiliency, hampers capital-raising terms, and limits strategic flexibility for funding development or commercialization initiatives.
Solasia Pharma KK News
4597 FAQ
What was Solasia Pharma KK’s price range in the past 12 months?
Solasia Pharma KK lowest stock price was ¥21.00 and its highest was ¥48.00 in the past 12 months.
What is Solasia Pharma KK’s market cap?
Solasia Pharma KK’s market cap is ¥7.10B.
When is Solasia Pharma KK’s upcoming earnings report date?
Solasia Pharma KK’s upcoming earnings report date is Aug 13, 2026 which is in 40 days.
How were Solasia Pharma KK’s earnings last quarter?
Solasia Pharma KK released its earnings results on May 15, 2026. The company reported -¥1.14 earnings per share for the quarter, missing the consensus estimate of N/A by -¥1.14.
Is Solasia Pharma KK overvalued?
According to Wall Street analysts Solasia Pharma KK’s price is currently Overvalued.
Does Solasia Pharma KK pay dividends?
Solasia Pharma KK does not currently pay dividends.
What is Solasia Pharma KK’s EPS estimate?
Solasia Pharma KK’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solasia Pharma KK have?
Solasia Pharma KK has 273,414,370 shares outstanding.
What happened to Solasia Pharma KK’s price movement after its last earnings report?
Solasia Pharma KK reported an EPS of -¥1.14 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Solasia Pharma KK?
Currently, no hedge funds are holding shares in JP:4597
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solasia Pharma KK
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Technical Analysis
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Modalis Therapeutics Corporation
―
Cyfuse Biomedical K.K.
―
Options Prices
Currently, No data available
---